Literature DB >> 15677698

Epidermal growth factor receptor inhibitors in colorectal cancer: it's time to get back on target.

Neal J Meropol.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15677698     DOI： 10.1200/JCO.2005.10.951

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  9 in total

1.  Protocol modifications influence the result of EGF receptor immunodetection by EGFR pharmDx in paraffin-embedded cancer tissues.

Authors:  Katalin Derecskei; Judit Moldvay; Krisztina Bogos; József Tímár
Journal:  Pathol Oncol Res       Date:  2006-12-25       Impact factor: 3.201

2.  Current status of treatment of metastatic colorectal cancer with special reference to cetuximab and elderly patients.

Authors:  Per Pfeiffer; Camilla Qvortrup; Jon K Bjerregaard
Journal:  Onco Targets Ther       Date:  2009-02-18       Impact factor: 4.147

3.  Circulating tumour cells as a predictive factor for response to systemic chemotherapy in patients with advanced colorectal cancer.

Authors:  Silke Lankiewicz; Silke Zimmermann; Christiane Hollmann; Tina Hillemann; Tim F Greten
Journal:  Mol Oncol       Date:  2008-09-16       Impact factor: 6.603

4.  Oncologists' response to new data regarding the use of epidermal growth factor receptor inhibitors in colorectal cancer.

Authors:  Efrat Dotan; Tianyu Li; Michael J Hall; Neal J Meropol; J Robert Beck; Yu-Ning Wong
Journal:  J Oncol Pract       Date:  2014-07-22       Impact factor: 3.840

Review 5.  Metastatic colorectal cancer: current systemic treatment options.

Authors:  Ruth E Board; Juan W Valle
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 6.  Biomarkers and anti-EGFR therapies for KRAS wild-type metastatic colorectal cancer.

Authors:  Jose A García-Sáenz; Javier Sastre; Eduardo Díaz-Rubio García
Journal:  Clin Transl Oncol       Date:  2009-11       Impact factor: 3.405

7.  Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer.

Authors:  J B Baker; D Dutta; D Watson; T Maddala; B M Munneke; S Shak; E K Rowinsky; L-A Xu; C T Harbison; E A Clark; D J Mauro; S Khambata-Ford
Journal:  Br J Cancer       Date:  2011-01-04       Impact factor: 7.640

8.  Immunohistochemical discrimination of wild-type EGFR from EGFRvIII in fixed tumour specimens using anti-EGFR mAbs ICR9 and ICR10.

Authors:  H Modjtahedi; S A Khelwatty; R S Kirk; A M Seddon; S Essapen; C A Del Vecchio; A J Wong; S Eccles
Journal:  Br J Cancer       Date:  2012-02-07       Impact factor: 7.640

9.  HER2 Expression Is Predictive of Survival in Cetuximab Treated Patients with RAS Wild Type Metastatic Colorectal Cancer.

Authors:  Said A Khelwatty; Soozana Puvanenthiran; Sharadah Essapen; Izhar Bagwan; Alan M Seddon; Helmout Modjtahedi
Journal:  Cancers (Basel)       Date:  2021-02-05       Impact factor: 6.639
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.